Compare BGX & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGX | TMCI |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.0M | 174.6M |
| IPO Year | N/A | 2021 |
| Metric | BGX | TMCI |
|---|---|---|
| Price | $11.82 | $2.90 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.07 |
| AVG Volume (30 Days) | 67.9K | ★ 814.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,879,000.00 |
| Revenue This Year | N/A | $3.25 |
| Revenue Next Year | N/A | $1.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.90 |
| 52 Week Low | $10.69 | $2.56 |
| 52 Week High | $12.44 | $10.79 |
| Indicator | BGX | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 33.49 |
| Support Level | $11.76 | $2.64 |
| Resistance Level | $11.90 | $3.15 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 65.22 | 59.77 |
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.